SeqLL (SEQL) Debt-to-Equity : 4.82 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SeqLL Debt-to-Equity?

SeqLL's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.63 Mil. SeqLL's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.30 Mil. SeqLL's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $0.61 Mil. SeqLL's debt to equity for the quarter that ended in Dec. 2023 was 4.82.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for SeqLL's Debt-to-Equity or its related term are showing as below:

SEQL' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.59 Med: -0.89 Max: 4.82
Current: 4.82

During the past 7 years, the highest Debt-to-Equity Ratio of SeqLL was 4.82. The lowest was -2.59. And the median was -0.89.

SEQL's Debt-to-Equity is ranked worse than
98.46% of 195 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22 vs SEQL: 4.82

SeqLL Debt-to-Equity Historical Data

The historical data trend for SeqLL's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SeqLL Debt-to-Equity Chart

SeqLL Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.89

-0.92

0.17

0.67

4.82

SeqLL Quarterly Data
	Dec18	Mar19	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.67	0.69	1.04	1.71	4.82

Competitive Comparison of SeqLL's Debt-to-Equity

For the Diagnostics & Research subindustry, SeqLL's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SeqLL's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SeqLL's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where SeqLL's Debt-to-Equity falls into.

SeqLL Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

SeqLL's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.633	+	1.298)	/	0.608
	=	4.82

SeqLL's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.633	+	1.298)	/	0.608
	=	4.82

SeqLL (OTCPK:SEQL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

SeqLL Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of SeqLL's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

SeqLL (SEQL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SeqLL Inc (OTCPK:SEQL) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Federal Street, Billerica, MA, USA, 01821

Website

http://www.seqll.com

SeqLL Inc is an early commercial-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple omics fields. The company leverages its expertise with True Single Molecule Sequencing (tSMS) technology enabling researchers and clinicians to contribute advancements to scientific research and development by accelerating one's understanding of the molecular mechanisms of disease and fundamental biological processes, It enables researchers to identify and synthesize DNA or RNA strands, irrespective of abundance, in a biological sample and is capable of analyzing billions of molecules in parallel.

Executives

Douglas Patrick Miscoll	director	317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
Daniel Robert Jones	officer: President, CEO	317 NEW BOSTON STREET, SUITE 210, WOBURN MA 01801
David Pfeffer	director	464 IVY AVENUE, HAWORTH NJ 07644
Patrice M. Milos	director	317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
Frances P Scally	officer: CHIEF FINANCIAL OFFICER	66 MELANIE LANE, SYOSSET NY 11791
John Whitcomb Kennedy	officer: CFO, Secretary	166 WINN STREET, WOBURN MA 01801